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Electrophysiologic Testing in Patients With Ventricular Tachycardia:
Past Performance and Future Expectations
ERIC N, PRYSTOWSKY, MD, FACC
Indianapolis, Indiana
Ventricular tachycardia is a relatively common arrhythmia
that often can lead to syncope or sudden death, Most
commonly, patients are given one or more antiarrhythmic
drugs, chosen empirically, and therapeutic efficacy is de-
termined by suppression of ventricular arrhythmias during
continuous electrocardiographic recording. Using this method,
therapy is considered successful if a significant (defined
differently in various studies) percent of premature ventric-
ular complexes are suppressed. However, depending on the
type of heart disease, mechanism of tachycardia, antiar-
rhythmic drug chosen and other factors, reduction in the
number of premature ventricular complexes mayor may not
accurately predict suppression of recurrent ventricular
tachycardia. Unfortunately, and all too often, patients ap-
parently treated successfully have recurrent syncope or die
suddenly.
Electrophysiologic testing as a clinical tool. To en-
hance predictive accuracy of drug therapy in patients with
supraventricular tachycardia, the method of serial electro-
physiologic drug testing was developed (1) and its use has
been extended to patients with recurrent sustained ventric-
ular tachycardia (2-4) and out of hospital cardiac arrest (5).
According to this method, patients are brought before drug
treatment to the electrophysiology laboratory, where elec-
trode catheters are positioned at multiple areas of the heart
and programmed electrical stimulation is employed to ini-
tiate ventricular tachycardia. After the initial study, drugs
are administered to the patient and programmed electrical
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stimulation is repeated. An ideal response is the inability to
initiate tachycardia during drug therapy, and many groups
(2-6) have shown that for most patients this response pre-
dicts no recurrence of ventricular tachycardia during out-
patient follow-up. Initial reports (3,4) suggested that, in a
small number of patients, induction of tachycardia during
conventional drug therapy predicted recurrence of arrhyth-
mia during follow-up. As noted by Hegeret al. (7), however,
initiation of ventricular tachycardia by programmed elec-
trical stimulation during amiodarone therapy does not by
itself predict drug failure.
The use of electrophysiologic testing as a clinical tool to
treat ventricular tachycardia and ventricular fibrillation has
increased dramatically over the past few years and much
has been learned about these arrhythmias. In 1972, Wellens
et al. (8) reported that ventricular tachycardia could be ini-
tiated and terminated with ventricular extrastimuli given
during ventricular pacing, and postulated that reentry was
the most likely mechanism for tachycardia in their patients.
In 1976, Wellens et al. (9) showed the importance of using
multiple pacing cycle lengths and pacing sites for the ini-
tiation of ventricular tachycardia. These observations on
ventricular tachycardia in human subjects were confirmed
and extended by Josephson et al. (10).
More recent work (6, II) has shown that in approximately
10% of patients, ventricular tachycardia not induced from
the right ventricle (using two extrastimuli) can be initiated
during programmed electrical stimulation of the left ven-
tricle. Further, in 10% of patients, programmed ventricular
stimulation with two extrastimuli and burst pacing did not
induce tachycardia during right ventricular apical pacing but
tachycardia was induced during pacing at the right ventric-
ular outflow tract (12). Although ventricular tachycardia can
be induced in over 90% of patients who have a history of
sustained ventricular tachycardia and coronary artery dis-
ease, in other forms of heart disease, for example cardio-
myopathy, the same pacing techniques initiate tachycardia
in approximately 50 to 60% of patients (6). In our experi-
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ence, more aggressive pacing techniques using three ex-
trastimuli increase the yield of ventricular tachycardia in-
duction , but commonly initiate nonclinical arrhythmias. More
work is necessary to define the specifi city and sensitivity of
the various pacing techniques.
Prediction of patients who would benefit from serial
electrophysiologic testing. One of the major advantages
of serial electrophysiologic drug testing is to define an ef-
fective antiarrhythmic regimen in a relatively short period
of time. However, this is no longer true for many patients,
some of whom spend 3 to 4 weeks in the hospital undergoing
multiple drug trials. Even then, for many patients a drug
regimen cannot be found that prevents induction of tachy-
cardia in the laboratory. The long hospitalization and re-
peated electrophysiologic testing are costly and stressful to
the patient. It would be very helpful to determine those
patients who, after initial invasive and noninvasive evalu-
ation, would benefit most from serial electrophysiologic
testing. The articles of Spielman et al. (13) and Swerdlow
et al. (14) address this issue.
Spielman et at. (13) evaluated multiple invasive and non-
invasive variables in 84 of120 pat ients studiedfor recurrent
sustained ventricular tachycardia. They used univariate and
multivariate statistical techniques to determine whether a
successful or unsuccessful medical response to serial elec-
trophysiologic testing could be predicted for a particular
patient. A successful medical response was no tachycardia
induced during drug therapy. Factors associated with suc-
cessful medical therapy were age less than 45 years, ejection
fraction greater than 50%, hypokinesia as the only contrac-
tion abnormality and absence of organic heart disease. Fac-
tors associated with medical failure were induction of ven-
tricular tachycardia with one ventricular extrastimulus, an
HV interval greater than 60 ms, presence of left ventricular
aneurysm and Q waves on the baseline electrocardiogram.
Although no single variable adequately predicted therapeutic
outcome, through the use of multiple variables in a dis-
criminant analysis 81% of all patients were classified cor-
rectly. The authors tested their discriminant function pro-
spectively in 31 patients: 19of 20 patients with low probability
of medical success were correctly identified as medical fail-
ures and 4 of 5 patients in the high probability of medical
success group were correctly classified. This interesting ar-
ticle has some limitations. First, 82% of the patients had
coronary artery disease and 61% had left ventricular aneu-
rysms. Therefore. the results from this highly select group
of patients may not be applicable to patients withother forms
of heart disease. Second, because only three patients were
given investigational drugs. the results from this study should
be extrapolated, at present, to patients treated with conven-
tional agents, although further testing may reveal a more
universal application of the authors' findings .
Sw erdlow et al. (14) also employed multivariate analysis
to predict patient responses to antiarrhythmic therapy dur-
ing serial electrophysiologic testing. An effective drug re-
sult was defined as induction of 5 or fewer repetitive ven-
tricular complexes during drug therapy. Ninety-six percent
of patients had a history of sustained ventricular tachycardia
and, as in the previous study, most patients (72%) had
coronary artery disease. Multiple variables were used but
the authors did not analyze electrophysiologic variables be-
cause one of their aims was to identify patients before any
electrophysiologic study was performed in whom serial
testing would be beneficial. No single variable was an ad-
equate predictor of drug response. A multivariate predictor
function, however, was constructed using extent of coronary
artery disease, sex and number of arrhythmia episodes, and
the positive predictive value was 52% with a negative pre-
dictive value of 81%. The authors prospectively applied the
predictor function to 25 patients and its major value appeared
to be the ability to predict accurately those patients with
low probability of success during serial testing. Thus, these
patients might be spared the expense and morbidity of repeat
electrophysiologic studies. Of note, both conventional and
investigational drugs were used in this study. As with the
study of Spielman et al. (13). the majority of patients had
coronary artery disease and caution should be used in ex-
trapolating these data to other patient groups. Further, the
authors' pacing protocol included the routine use of three
extrastimuli in control and drug studies. It is quite possible
that this technique is overly aggressive and lacks specificity.
Thus, patients considered drug failures might have been
drug successes had the authors used no more than two ex-
trastimuli. More work is needed to define the sensitivity and
specifi city of this pacing technique.
Spielman et al. and Swerdlow et al. used multivariate
analysis to develop a discriminant function for predicting
response to drug therapy in patients with sustained ventric-
ular tachycardia and, for the most part, coronary artery
disease. Although all variables analyzed were not the same
for both studies, the significance of identical variables dif-
fered. For example, sex was incorporated into the predictor
function of Swerdlow et al. and age was used in the dis-
criminant function of Spielman et al. Ideally, one would
like to develop a discriminant function that could be applied
to the majority of patients with ventricular tachycardia re-
gardless of etiology. Obviously. this will be difficult to
achieve but deserves further study.
Predictive factors other than induction of tachy-
cardia. One last point must be addressed. An assumption
used in both studies is that induction of ventricular tachy-
cardia while the patient is receiving drug therapy portends
failure of that drug to prevent recurrent ventricular tachy-
cardia during follow-up. This dogma. based on a relatively
small number of patients, has been perpetuated since the
start of serial electrophysiologic testing for ventricular
tachycardia. Clearly, patients discharged who still have
tachycardia induced during drug therapy will more fre-
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quently have recurrence of arrhythmia than those patients
in whom tachycardia can be suppressed. Our observation
(7) that induction of ventricular tachycardia during amio-
darone therapy does not necessarily predict a poor clinical
response demonstrates that factors other than tachycardia
induction may be important predictors of successful clinical
outcome. We (15) recently analyzed multiple variables in
patients discharged with ventricular tachycardia still indu-
cible during amiodarone therapy, and developed a discrim-
inant function to predict drug success. Approximately 60%
of our patients had no recurrence of tachycardia during a
mean follow-up period of 14 months, and using the dis-
criminant function the clinical outcome was predicted with
90% accuracy. Importantly, all patients who had recurrence
of ventricular tachycardia were classified correctly. We cur-
rently use this discriminant function to determine which
patients receiving amiodarone therapy can be safely sent
home even when ventricular tachycardia is induced in the
electrophysiology laboratory. Whether discriminant func-
tion analysis can be used to predict drug efficacy with other
antiarrhythmic drugs requires further investigation, but pre-
liminary data using propafenone, an investigational antiar-
rhythmic drug, suggests that this form of analysis may have
predictive accuracy (16).
The preliminary studies of Spielman et al. and Swerdlow
et al. provide important new information and a foundation
for subsequent investigations. It is hoped that electrophys-
iologists will soon be able to select patients most likely to
benefit from serial testing, as well as define more accurately
drug efficacy in the many patients in whom no drug prevents
induction of ventricular tachycardia during programmed
electrical stimulation.
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